Loco-regional recurrence following mastectomy for early breast carcinoma: efficacy of radiotherapy at the time of recurrence

被引:10
作者
Chaudary, MA
Tong, D
Millis, R
Smith, P
Fentiman, IS
Rubens, RD
机构
[1] Imperial Cancer Research Fund, Department of Clinical Oncology Unit, Guy's Hospital
[2] ICRF, Department of Clinical Oncology, Guy's Hospital
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 1997年 / 23卷 / 04期
关键词
mastectomy; post-operative radiotherapy; loco-regional recurrence;
D O I
10.1016/S0748-7983(97)90939-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aims to define the risk factors for loco-regional relapse following mastectomy, and to assess the efficacy of radiotherapy at the time of relapse, To achieve this 272 patients with loco-regional relapse treated at a single institution with modified radical or radical mastectomy were reviewed. Tumour size, axillary node involvement and tumour grade were found to be significant risk factors for loco-regional recurrence of disease, Radiotherapy given at the time of relapse controlled disease in 61% of cases, compared with 34% of patients treated with systemic treatment only, Altogether, 146 (54%) of the 269 evaluable patients with local failure had uncontrolled disease at the same site, either at the time of death or at the date last seen. The result of this retrospective study showed that delayed radiotherapy was effective in controlling the disease in patients with developing loco-regional relapses, However, as adjuvant radiotherapy reduces the incidence of local disease recurrence it should be recommended to patients considered to be at high risk of local relapse following mastectomy; namely those with tumours bigger than 5 cm with four or more positive axillary modes.
引用
收藏
页码:348 / 353
页数:6
相关论文
共 42 条
[1]  
ABERIZK WJ, 1986, CANCER, V58, P1214, DOI 10.1002/1097-0142(19860915)58:6<1214::AID-CNCR2820580607>3.0.CO
[2]  
2-9
[3]   A PRELIMINARY ASSESSMENT OF FACTORS ASSOCIATED WITH RECURRENT DISEASE IN A SURGICAL ADJUVANT CLINICAL-TRIAL FOR PATIENTS WITH BREAST-CANCER WITH SPECIAL EMPHASIS ON THE AGGRESSIVENESS OF THERAPY [J].
AHMANN, DL ;
OFALLON, JR ;
SCANLON, PW ;
PAYNE, WS ;
BISEL, HF ;
EDMONSON, JH ;
FRYTAK, S ;
HAHN, RG ;
INGLE, JN ;
RUBIN, J ;
CREAGAN, ET .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (04) :371-381
[4]  
ARIEL I, 1979, J SURG ONCOL, V12, P127
[5]   POST-MASTECTOMY MEGAVOLTAGE RADIOTHERAPY - THE OSLO AND STOCKHOLM TRIALS [J].
AUQUIER, A ;
RUTQVIST, LE ;
HOST, H ;
ROTSTEIN, S ;
ARRIAGADA, R .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :433-437
[6]  
BEDWINEK JM, 1981, CANCER, V47, P2232, DOI 10.1002/1097-0142(19810501)47:9<2232::AID-CNCR2820470921>3.0.CO
[7]  
2-R
[8]   THE COMBINATION OF RADIOTHERAPY, ADJUVANT CHEMOTHERAPY (CYCLOPHOSPHAMIDE-DOXORUBICIN-FTORAFUR) AND TAMOXIFEN IN STAGE-II BREAST-CANCER - LONG-TERM FOLLOW-UP RESULTS OF A RANDOMIZED TRIAL [J].
BLOMQVIST, C ;
TIUSANEN, K ;
ELOMAA, I ;
RISSANEN, P ;
HIETANEN, T ;
HEINONEN, E ;
GROHN, P .
BRITISH JOURNAL OF CANCER, 1992, 66 (06) :1171-1176
[9]   10-YEAR EXPERIENCE WITH CMF-BASED ADJUVANT CHEMOTHERAPY IN RESECTABLE BREAST-CANCER [J].
BONADONNA, G ;
VALAGUSSA, P ;
ROSSI, A ;
TANCINI, G ;
BRAMBILLA, C ;
ZAMBETTI, M ;
VERONESI, U .
BREAST CANCER RESEARCH AND TREATMENT, 1985, 5 (02) :95-115
[10]  
CHEN KKY, 1985, CANCER, V56, P1269, DOI 10.1002/1097-0142(19850915)56:6<1269::AID-CNCR2820560608>3.0.CO